With a passion for social responsibility and providing clear, commercially aware legal advice, Linda has been working with Better Collective to bring transparency and fairness to the iGaming industry for the last 3 years.
Driving the Group’s global regulatory compliance and responsible marketing strategy, as well as leading GDPR-readiness initiatives and supporting the Group’s intensive M&A activity and IPO preparations means she has insight into a diverse range of challenges in an increasingly complex regulatory landscape.
Patrick is a senior associate in Wiggin’s Betting and Gaming team, specialising in data protection. Patrick has provided GDPR advice to a wide range of clients in the gambling sector – including operators, white labels and B2B providers – as well as providing data protection advice to clients in the film, technology, and media sectors. Patrick’s data protection advice includes compliance, contract drafting and negotiation, and ICO investigations across all aspects of GDPR and electronic direct marketing.
Patrick is a Certified Practitioner of Data Protection, gaining a distinction from PDP.
A long time security and privacy advocate, Mika has applied his trade in everything from logistics and embedded systems all the way to real-time gambling.
At Smarkets he focuses on the cross-section of security, usability and compliance, with an aim at keeping things practical. An engineer at heart, he likes to automate the mundane so people can focus on the subtle. And as the DPO he helps to balance the needs of competing requirements so that both engineering and compliance are satisfied.
He knows that while everyone says they want security, in reality they want convenience. So, Mika has made it his mission to ensure the two wants are not mutually exclusive.
Tom joined Smarkets shortly after its launch in 2010 and has overseen the company’s customer service, finance, legal and compliance functions during crucial growth-phases of the company. Smarkets is one of the world’s leading betting exchange and prediction market platforms, making peer-to-peer trading on events secure, efficient and exciting. Headquartered in London, with offices in Los Angeles and Malta, the company was founded by a team of finance and software engineering professionals and is backed by Passion Capital and Deutsche Telekom. The Smarkets exchange has processed over £10 billion worth of transactions for customers across the company’s licensed and regulated markets.
Ying Cai is a Director of Supply Chain at Ashvattha Therapeutics with 16 years industrial experience, specializing in clinical supply chain. Ying uses that experience to ensure end to end supply chain efficiency and integrity from raw materials to patients.
Dr. Heidi Hoffmann, Executive Director, CMC and Supply Chain at Sutro Biopharma, has 26 years of experience in biotechnology, specializing in process development, technology transfer, and manufacturing of vaccines and biological therapeutics. Directly after receiving her Ph.D. from University of California, Berkeley, Dr. Hoffmann began her career at Aviron, where she worked on process development and production of vaccines for EBV, PIV, and influenza (FluMist). She then joined Valentis, where she led the team responsible for process development, technology transfer, and clinical production of plasmid DNA for gene therapy. In 2002, Dr. Hoffmann returned to vaccine work by joining VaxGen, where she was responsible for process development and manufacturing of anthrax vaccine. Later, she transitioned into a technology transfer role, hiring and leading the VaxGen oversight team for the successful transfer of commercial production of Bristol-Meyer Squibb’s Orencia (abatacept) into the Celltrion manufacturing facility in South Korea. After the completion of that project, Dr. Hoffmann joined non-profit Global Solutions for Infectious Diseases (GSID) as Project Director responsible for coordinating the outsourcing of process development and manufacture of HIV vaccines. Dr. Hoffmann joined Sutro in February 2011 and currently heads CMC and directs outsourced cGMP manufacturing for protein therapeutics and ADCs produced using Sutro’s proprietary cell-free protein expression system
